These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 33091133)
1. The immunorecognition, subcellular compartmentalization, and physicochemical properties of nucleic acid nanoparticles can be controlled by composition modification. Johnson MB; Halman JR; Miller DK; Cooper JS; Khisamutdinov EF; Marriott I; Afonin KA Nucleic Acids Res; 2020 Nov; 48(20):11785-11798. PubMed ID: 33091133 [TBL] [Abstract][Full Text] [Related]
2. Assessment of Intracellular Compartmentalization of RNA Nanostructures. Radwan Y; Afonin KA; Johnson MB Methods Mol Biol; 2023; 2709():211-228. PubMed ID: 37572283 [TBL] [Abstract][Full Text] [Related]
3. Discriminating Immunorecognition Pathways Activated by RNA Nanostructures. Danai L; Johnson MB; Afonin KA Methods Mol Biol; 2023; 2709():229-240. PubMed ID: 37572284 [TBL] [Abstract][Full Text] [Related]
5. Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles. Hong E; Halman JR; Shah AB; Khisamutdinov EF; Dobrovolskaia MA; Afonin KA Nano Lett; 2018 Jul; 18(7):4309-4321. PubMed ID: 29894623 [TBL] [Abstract][Full Text] [Related]
6. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786 [TBL] [Abstract][Full Text] [Related]
7. Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights. Rebolledo LP; Ke W; Cedrone E; Wang J; Majithia K; Johnson MB; Dokholyan NV; Dobrovolskaia MA; Afonin KA ACS Appl Mater Interfaces; 2024 Feb; 16(7):8430-8441. PubMed ID: 38344840 [TBL] [Abstract][Full Text] [Related]
8. Break to Build: Isothermal Assembly of Nucleic Acid Nanoparticles (NANPs) Beasock D; Ha A; Halman J; Panigaj M; Wang J; Dokholyan NV; Afonin KA Bioconjug Chem; 2023 Jun; 34(6):1139-1146. PubMed ID: 37293781 [TBL] [Abstract][Full Text] [Related]
9. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells. Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721 [TBL] [Abstract][Full Text] [Related]
10. The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells. Bila D; Radwan Y; Dobrovolskaia MA; Panigaj M; Afonin KA Molecules; 2021 Jul; 26(14):. PubMed ID: 34299506 [TBL] [Abstract][Full Text] [Related]
11. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs). Nordmeier S; Ke W; Afonin KA; Portnoy V Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137 [TBL] [Abstract][Full Text] [Related]
12. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles. Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772 [TBL] [Abstract][Full Text] [Related]
13. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution. Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854 [TBL] [Abstract][Full Text] [Related]
14. Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects. Johnson MB; Chandler M; Afonin KA Adv Drug Deliv Rev; 2021 Jun; 173():427-438. PubMed ID: 33857556 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Nonmodified Wireframe DNA Origami for Acute Toxicity and Biodistribution in Mice. Wamhoff EC; Knappe GA; Burds AA; Du RR; Neun BW; Difilippantonio S; Sanders C; Edmondson EF; Matta JL; Dobrovolskaia MA; Bathe M ACS Appl Bio Mater; 2023 May; 6(5):1960-1969. PubMed ID: 37040258 [TBL] [Abstract][Full Text] [Related]
16. Change in Lipofectamine Carrier as a Tool to Fine-Tune Immunostimulation of Nucleic Acid Nanoparticles. Newton HS; Radwan Y; Xu J; Clogston JD; Dobrovolskaia MA; Afonin KA Molecules; 2023 Jun; 28(11):. PubMed ID: 37298960 [TBL] [Abstract][Full Text] [Related]
17. Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro. Juneja R; Vadarevu H; Halman J; Tarannum M; Rackley L; Dobbs J; Marquez J; Chandler M; Afonin K; Vivero-Escoto JL ACS Appl Mater Interfaces; 2020 Sep; 12(35):38873-38886. PubMed ID: 32805923 [TBL] [Abstract][Full Text] [Related]